Criteo S.A.
$539.31M- Market cap
- $867.75M
- Debt
- +$36.84M
- Cash
- −$365.28M
Capital structure 96% equity / 4% debt · EV / Revenue 0.28x · EV / EBITDA 1.62x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $867.75M · View financials
Snapshot Sep 8, 2026, 1:55 PM ET
FY 2025 ·
Decision snapshot: CRTO stock price vs JAZZ: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at JAZZ's multiple
Needs JAZZ P/E.
Implied fair value · at CRTO's multiple
Needs Annual EPS is negative.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CRTO FY 2025 (ended Dec 31, 2025) · JAZZ FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / Revenue 0.28x · EV / EBITDA 1.62x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CRITEO S.A. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Jazz Pharmaceuticals plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.03x
1.48x
Net debt / EBITDA
Leverage against operating earnings
-0.99x
15.80x
Cash and equivalents
Liquid reserves on the balance sheet
$365.28M
$1.39B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Trade Desk, Inc.
CRTO vs TTD
MAGNITE, INC.
CRTO vs MGNI
PubMatic, Inc.
CRTO vs PUBM
AMGEN INC
CRTO vs AMGN
GILEAD SCIENCES, INC.
CRTO vs GILD
VERTEX PHARMACEUTICALS INC / MA
CRTO vs VRTX
SUPERNUS PHARMACEUTICALS, INC.
CRTO vs SUPN
Vanda Pharmaceuticals Inc.
CRTO vs VNDA
PERRIGO Co plc
CRTO vs PRGO
$36.84M
$6.39B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.